drugset / Trial / NCT06079671
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Phase 3
Recruiting
800 enrolled
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGynecologic Oncology Group Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Timeline
- Start
- 2023-09-22
- Primary completion
- 2027-11-26
- Completion
- 2030-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volrustomig | Monoclonal antibody | — | Intravenous |